153 related articles for article (PubMed ID: 35357160)
21. Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
Lai A; Kahraman M; Govek S; Nagasawa J; Bonnefous C; Julien J; Douglas K; Sensintaffar J; Lu N; Lee KJ; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Moon MJ; Joseph JD; Darimont B; Brigham D; Grillot K; Heyman R; Rix PJ; Hager JH; Smith ND
J Med Chem; 2015 Jun; 58(12):4888-904. PubMed ID: 25879485
[TBL] [Abstract][Full Text] [Related]
22. Discovery of Novel ERα and Aromatase Dual-Targeting PROTAC Degraders to Overcome Endocrine-Resistant Breast Cancer.
Xin L; Wang C; Cheng Y; Wang H; Guo X; Deng X; Deng X; Xie B; Hu H; Min C; Dong C; Zhou HB
J Med Chem; 2024 Jun; 67(11):8913-8931. PubMed ID: 38809993
[TBL] [Abstract][Full Text] [Related]
23. Identification of Novel Dual-Target Estrogen Receptor α Degraders with Tubulin Inhibitory Activity for the Treatment of Endocrine-Resistant Breast Cancer.
Deng X; Deng X; Ning W; Xin L; Li Q; Hu Z; Xie B; Liang K; Min C; Dong C; Huang J; Zhou HB
J Med Chem; 2023 Aug; 66(16):11094-11117. PubMed ID: 37584263
[TBL] [Abstract][Full Text] [Related]
24. Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.
Nagasawa J; Govek S; Kahraman M; Lai A; Bonnefous C; Douglas K; Sensintaffar J; Lu N; Lee K; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Joseph JD; Darimont B; Brigham D; Maheu K; Heyman R; Rix PJ; Hager JH; Smith ND
J Med Chem; 2018 Sep; 61(17):7917-7928. PubMed ID: 30086626
[TBL] [Abstract][Full Text] [Related]
25. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
26. Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.
Luo G; Lin X; Ren S; Wu S; Wang X; Ma L; Xiang H
Eur J Med Chem; 2021 Dec; 226():113870. PubMed ID: 34610548
[TBL] [Abstract][Full Text] [Related]
27. Activity of the antiestrogenic cajanin stilbene acid towards breast cancer.
Fu Y; Kadioglu O; Wiench B; Wei Z; Wang W; Luo M; Yang X; Gu C; Zu Y; Efferth T
J Nutr Biochem; 2015 Nov; 26(11):1273-82. PubMed ID: 26365581
[TBL] [Abstract][Full Text] [Related]
28. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models.
Garner F; Shomali M; Paquin D; Lyttle CR; Hattersley G
Anticancer Drugs; 2015 Oct; 26(9):948-56. PubMed ID: 26164151
[TBL] [Abstract][Full Text] [Related]
29. In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells.
Busonero C; Leone S; Bianchi F; Acconcia F
Cell Oncol (Dordr); 2018 Dec; 41(6):677-686. PubMed ID: 30182339
[TBL] [Abstract][Full Text] [Related]
30. SERDs: a case study in targeted protein degradation.
Wang L; Sharma A
Chem Soc Rev; 2022 Oct; 51(19):8149-8159. PubMed ID: 36073297
[TBL] [Abstract][Full Text] [Related]
31. Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists.
Scott JS; Stead D; Barlaam B; Breed J; Carbajo RJ; Chiarparin E; Cureton N; Davey PRJ; Fisher DI; Gangl ET; Grebe T; Greenwood RD; Hande S; Hatoum-Mokdad H; Hughes SJ; Hunt TA; Johnson T; Kavanagh SL; Klinowska TCM; Larner CJB; Lawson M; Lister AS; Longmire D; Marden S; McGuire TM; McMillan C; McMurray L; Morrow CJ; Nissink JWM; Moss TA; O'Donovan DH; Polanski R; Stokes S; Thakur K; Trueman D; Truman C; Tucker MJ; Wang H; Whalley N; Wu D; Wu Y; Yang B; Yang W
J Med Chem; 2023 Feb; 66(4):2918-2945. PubMed ID: 36727211
[TBL] [Abstract][Full Text] [Related]
32. Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer.
Bai C; Ren S; Wu S; Zhu M; Luo G; Xiang H
Eur J Med Chem; 2021 Oct; 221():113543. PubMed ID: 34022716
[TBL] [Abstract][Full Text] [Related]
33. VAV3 mediates resistance to breast cancer endocrine therapy.
Aguilar H; Urruticoechea A; Halonen P; Kiyotani K; Mushiroda T; Barril X; Serra-Musach J; Islam A; Caizzi L; Di Croce L; Nevedomskaya E; Zwart W; Bostner J; Karlsson E; Pérez Tenorio G; Fornander T; Sgroi DC; Garcia-Mata R; Jansen MP; García N; Bonifaci N; Climent F; Soler MT; Rodríguez-Vida A; Gil M; Brunet J; Martrat G; Gómez-Baldó L; Extremera AI; Figueras A; Balart J; Clarke R; Burnstein KL; Carlson KE; Katzenellenbogen JA; Vizoso M; Esteller M; Villanueva A; Rodríguez-Peña AB; Bustelo XR; Nakamura Y; Zembutsu H; Stål O; Beijersbergen RL; Pujana MA
Breast Cancer Res; 2014 May; 16(3):R53. PubMed ID: 24886537
[TBL] [Abstract][Full Text] [Related]
34. Hot-Spot Residue-Based Virtual Screening of Novel Selective Estrogen-Receptor Degraders for Breast Cancer Treatment.
Dai R; Bao X; Zhang Y; Huang Y; Zhu H; Yang K; Wang B; Wen H; Li W; Liu J
J Chem Inf Model; 2023 Dec; 63(23):7588-7602. PubMed ID: 37994801
[TBL] [Abstract][Full Text] [Related]
35. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
36. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
[TBL] [Abstract][Full Text] [Related]
37. Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancer.
Thewes V; Simon R; Schroeter P; Schlotter M; Anzeneder T; Büttner R; Benes V; Sauter G; Burwinkel B; Nicholson RI; Sinn HP; Schneeweiss A; Deuschle U; Zapatka M; Heck S; Lichter P
Cancer Res; 2015 Feb; 75(4):720-31. PubMed ID: 25643697
[TBL] [Abstract][Full Text] [Related]
38. Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.
Lu Y; Liu W
J Med Chem; 2020 Dec; 63(24):15094-15114. PubMed ID: 33138369
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility.
Guan J; Zhou W; Hafner M; Blake RA; Chalouni C; Chen IP; De Bruyn T; Giltnane JM; Hartman SJ; Heidersbach A; Houtman R; Ingalla E; Kategaya L; Kleinheinz T; Li J; Martin SE; Modrusan Z; Nannini M; Oeh J; Ubhayakar S; Wang X; Wertz IE; Young A; Yu M; Sampath D; Hager JH; Friedman LS; Daemen A; Metcalfe C
Cell; 2019 Aug; 178(4):949-963.e18. PubMed ID: 31353221
[TBL] [Abstract][Full Text] [Related]
40. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
Lainé M; Fanning SW; Chang YF; Green B; Greene ME; Komm B; Kurleto JD; Phung L; Greene GL
Breast Cancer Res; 2021 May; 23(1):54. PubMed ID: 33980285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]